Stock Rating Downgrade
In the last week the Value Trend Rating for Neurocrine Biosciences Inc (NASDAQ: NBIX) weakened from B to C reflecting eroding fundamentals and low Appreciation Potential.
Recent Price Action
On 1/5/24, Neurocrine Biosciences Inc (NASDAQ: NBIX) stock declined slightly by -0.8%, closing at $132.48. This decline was accompanied by normal trading volume. Relative to the market the stock has been exceptionally strong over the last nine months but is unchanged during the last week.
Current PriceTarget Research Rating
NBIX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Neurocrine Biosciences has a current Value Trend Rating of C (High Neutral). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Neurocrine Biosciences has a neutral Appreciation Score of 41 but a very high Power Rating of 86, producing the High Neutral Value Trend Rating.
Be the first to comment